Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC
- PMID: 35590196
- DOI: 10.1016/j.medj.2021.10.005
Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC
Abstract
The therapeutic landscape of epidermal growth factor receptor (EGFR)-mutation-positive non-small cell lung cancer (NSCLC) is continually evolving. A recent manuscript in Nature by Robichaux and colleagues1 reports on a structure-based classification of EGFR mutations to help predict sensitivities to EGFR inhibitors in NSCLC that may ultimately improve patient outcomes.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests E.G. has consulting or advisory roles at ABL Bio, Boehringer Ingelheim, Bristol Myers Squibb, Dracen Pharmaceuticals, Eisai, Eli Lilly, EMD Serono, GSK, Merck, Natera, Novartis, Regeneron, Sanofi, Shionogi, and Xilio Therapeutics. A.G. declares no competing interests.
Comment on
-
Structure-based classification predicts drug response in EGFR-mutant NSCLC.Nature. 2021 Sep;597(7878):732-737. doi: 10.1038/s41586-021-03898-1. Epub 2021 Sep 15. Nature. 2021. PMID: 34526717 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
